[Recent progress of matrix metalloproteinase (MMP) research and its clinical application for cancer therapy].
The matrix metalloproteinases (MMPs) are a family of secreted and membrane-bound zinc-endopeptidases. These enzymes are capable of degrading the extracellular matrix, including collagens, laminin, proteoglycan and fibronectin. In some human cancers, a positive correlation has been demonstrated between MMP expression and the likelihood of developing metastasis. An imbalance between MMPs and the tissues inhibitor of metalloproteinases (TIMPs) may play a significant role in the invasive phenotype of cancers. Although TIMPs have been shown to inhibit tumor metastasis in some in vivo models, they are not suitable for pharmacologic applications due to their short half-life in vivo and large molecular size. In this paper, recent advances in MMP research and reports of clinical applications of synthetic MMP inhibitors for cancer patients are reviewed.
Otani
Y
Y
Dept. of Surgery, School of Medicine, Keio University, Japan.
Fujii
M
M
Kubota
T
T
Kitajima
M
M
Okada
Y
Y
D006801:Humans; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000502:physiology; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019714:Tissue Inhibitor of Metalloproteinases / Q000737:chemistry / Q000145:classification / Q000627:therapeutic use
D019714:Tissue Inhibitor of Metalloproteinases; D008666:Metalloendopeptidases